Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Geron Corporation is a biopharmaceutical company focused on developing telomerase inhibitors for hematologic malignancies. Its flagship product, RYTELO (imetelstat), targets blood cancers like myelodysplastic syndromes and myelofibrosis, aiming to modify disease progression. The company leverages Nobel-winning science, holds key patents, and operates in the U.S. and Europe, emphasizing innovative therapies with potential for significant market impact and regulatory exclusivity.
This description was generated via AI from an annual report. Updated about 1 year ago.